Eli Lilly Launches Platform for AI-Enabled Drug Discovery

Lilly to give biotech startups access to AI tools

Insitro, Firefly Bio and Superluminal Medicines are among the first participants in Lilly’s “TuneLabs” platform, which the pharma says can help young drugmakers while training its own models.

Lilly offers AI discovery models to biotech partners

Eli Lilly is offering AI-powered drug discovery models developed at a cost of around $1 billion to biotech companies for free

Eli Lilly launches platform for AI-enabled drug discovery

(Reuters) -Drugmaker Eli Lilly said on Tuesday it is launching an artificial intelligence and machine learning platform that provides biotech companies access to drug discovery models trained on years of Lilly’s research data. (Reporting by Christy Santhosh in Bengaluru; Editing by Harikrishnan Nair)

insitro Partners with Lilly to Build First-in-Kind Machine Learning Models to Advance Small Molecule Drug Discovery

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sep 9, 2025-

Lilly will let small biotechs use its AI models at no cost

Lilly launches TuneLab to make its proprietary artificial intelligence models available at no cost to selected biotechs

Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the launch of Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform...